Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Freeline Therapeutics Limited is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The data indicates that this prosecution activity is limited to 1 distinct examiner and 1 distinct art unit. This suggests a targeted approach to the company's current patent filings with all active matters residing in a single technical division.
The busiest examiner for the portfolio is BOWERS, ERIN M, who is assigned 1 busiest examiner pending office action. As there is only 1 distinct examiner listed for the entire portfolio, BOWERS, ERIN M is handling all of the company's current pending actions. This means the company's immediate patent outcomes are tied to the specific examination style of this individual.
The presence of 1 distinct art unit confirms that the technical subject matter is being reviewed within a single specialized group. With 1 pending office action in total, the portfolio's current activity is centralized. Practitioners can focus their attention on the requirements of the 1 distinct examiner to resolve the company's current pending matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOWERS, ERIN M | 1 | 54.7% | +9.8% |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17795767 | IMPROVED ASSAY FOR DETERMINING NEUTRALISING ANTIBODY TITRE TO A VIRAL VECTOR | BOWERS, ERIN M | 1653 | §103 | Final Rejection | — | Pending | Jul 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFreeline Therapeutics Limited has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Erin M Bowers has the most, with 1 of Freeline Therapeutics Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.